Eli Lilly and Company

Eli Lilly and Company

LLY

$1,431.23

Updated: 04/11/2026, 15:38:38

Market Cap
$1.35T
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

USD
NYSE
CEO: David A. Ricks
Employees: 50,000
https://www.lilly.com
Asset Summaries
Latest generated summaries for LLY

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
LLY-10-k-fy2025.html2.3 MBtext/htmlENFiled 12/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 34 KPI observations

Revenue

N/A

FY — · Reported

Net income

$20.6B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

N/A

FY — · Reported

R&D intensity

N/A

FY — · Reported

Share repurchases

$4.1B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Cardiometabolic pipeline: tirzepatide new indications
Cardiometabolic health product family
Oncology product family
Immunology and neuroscience product families
Orforglipron submitted and in Phase 3 across multiple indications
Other cardiometabolic pipeline compounds
Immunology pipeline: mirikizumab and lebrikizumab
Revenue contract types and collaboration with Boehringer Ingelheim
Neuroscience pipeline: donanemab and others
Oncology pipeline: imlunestrant, pirtobrutinib, olomorasib, FRα ADC
Orforglipron regulatory submissions

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Single-segment human pharmaceutical business

Eli Lilly discovers, develops, manufactures, and markets products in a single business segment—human pharmaceutical products; incorporated in 1901 in Indiana, succeeding business founded 1876.

98%
Source evidence
“We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.”

Single operating segment

Single operating segment: discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide

98%
Source evidence
“We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.”

Customer payment terms

Payment terms in most major jurisdictions typically range from 30 to 70 days from date of shipment

95%
Source evidence
“Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment.”

U.S. customer/channel base

Account managers service wholesalers, PBMs, insurers, plan sponsors, employers, managed care organizations, GPOs, government and long-term care institutions, hospitals, and certain retail pharmacies, often with discounts or rebates; in the U.S. most products are distributed through wholesalers.

95%
Source evidence
“In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals.”

LillyDirect direct-to-patient digital platform

LillyDirect direct-to-patient digital health platform delivers select medicines dispensed by third-party pharmacies; sales a growing portion of business in 2025.

97%
Source evidence
“Sales through LillyDirect represented a growing portion of our business in 2025”

Cardiometabolic pipeline: tirzepatide new indications

Tirzepatide (Mounjaro, Zepbound): HFpEF approved in EU; pediatric/adolescent T2D approved in US and EU; CV outcomes submitted in US; MASLD, obesity morbidity/mortality, and T1D in Phase 3

98%
Source evidence
“Tirzepatide (Mounjaro, Zepbound)Heart failure with preserved ejection fractionApproved”

Cardiometabolic health product family

Cardiometabolic products: Basaglar, Humalog family, Humulin, Jardiance (with Boehringer Ingelheim), Mounjaro, Trulicity, Zepbound (obesity and obstructive sleep apnea).

98%
Source evidence
“Zepbound For the treatment of adults with obesity or overweight with at least one weight-related comorbid condition”

Oncology product family

Oncology products: Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, Tyvyt (with Innovent, China), Verzenio.

98%
Source evidence
“Verzenio For use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer”

Immunology and neuroscience product families

Immunology: Ebglyss (with Almirall in Europe), Olumiant (with Incyte), Omvoh, Taltz. Neuroscience: Emgality (migraine), Kisunla (early Alzheimer's disease).

98%
Source evidence
“Kisunla For adults with early symptomatic Alzheimer's disease with confirmed amyloid pathology”

Orforglipron submitted and in Phase 3 across multiple indications

Orforglipron: obesity and T2D submitted (US/EU/Japan); CV outcomes, hypertension, OSA, osteoarthritis pain, PAD, stress urinary incontinence in Phase 3

97%
Source evidence
“OrforglipronObesity(1) SubmittedSubmitted in the U.S., the EU, and Japan.”

Other cardiometabolic pipeline compounds

Efsitora alfa (T2D) submitted in US/EU/Japan; eloralintide, lepodisiran, muvalaplin, and retatrutide in Phase 3 across cardiometabolic indications

96%
Source evidence
“Insulin efsitora alfa Type 2 diabetesSubmittedSubmitted in the U.S., the EU, and Japan.”

Immunology pipeline: mirikizumab and lebrikizumab

Mirikizumab (Omvoh) approved for Crohn's disease in US, EU, Japan; lebrikizumab in Phase 3 for perennial allergen AR and CRSwNP, in collaboration with Almirall in Europe

95%
Source evidence
“Mirikizumab (Omvoh)Crohn's diseaseApprovedApproved in the U.S., the EU, and Japan.”

Revenue contract types and collaboration with Boehringer Ingelheim

Revenue from product sales plus collaborations/other; collaboration revenue includes Boehringer Ingelheim collaboration and sale of product rights

95%
Source evidence
“Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim, as well as the sale of product rights.”

Neuroscience pipeline: donanemab and others

Donanemab (Kisunla) approved for early Alzheimer's in US, EU, Japan with pre-clinical AD in Phase 3; brenipatide, ixo-vec (via Adverum acquisition), and remternetug in Phase 3

95%
Source evidence
“Donanemab (Kisunla)Early Alzheimer's diseaseApprovedApproved in the U.S., the EU, and Japan.”

Oncology pipeline: imlunestrant, pirtobrutinib, olomorasib, FRα ADC

Imlunestrant (Inluriyo) and pirtobrutinib (Jaypirca) approved; olomorasib (KRAS G12C NSCLC) and sofetabart mipitecan (FRα ADC) in Phase 3 with FDA Breakthrough Therapy designations

95%
Source evidence
“Imlunestrant (Inluriyo)ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerApprovedApproved in the U.S., the EU, and Japan.”

Orforglipron regulatory submissions

Orforglipron: highly anticipated product candidate submitted to regulatory agencies

90%
Source evidence
“We regularly submit new product candidates and indications to regulatory agencies for approval, including highly anticipated candidates such as orforglipron.”

Revenue by type (2023-2025)

Net product revenue $60,958M (2025), $40,748M (2024), $28,814M (2023); Collaboration and other revenue $4,221M / $4,295M / $5,310M; total $65,179M / $45,043M / $34,124M

98%
Source evidence
“Net product revenue$60,958 $40,748 $28,814 Collaboration and other revenue4,221 4,295 5,310 Revenue$65,179 $45,043 $34,124”

Operations and dependencies

Manufacturing and distribution footprint

Products manufactured and distributed through facilities in the U.S. (incl. Puerto Rico), Europe, and Asia; sold in approximately 90 countries.

97%
Source evidence
“We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 90 countries.”

Positioning and strategy

Cash paid for acquisitions

Cash paid for acquisitions, net of cash acquired: $661M (2025), $948M (2024), $1,044M (2023)

94%
Source evidence
“Cash paid for acquisitions, net of cash acquired(661)(948)(1,044)”

Acquisition of Adverum Biotechnologies, Inc.

Ixo-vec for wet AMD was acquired in the acquisition of Adverum Biotechnologies, Inc.; Phase 3 ongoing

92%
Source evidence
“Acquired in the acquisition of Adverum Biotechnologies, Inc. Phase 3 trial is ongoing.”

Property and equipment purchases

Purchases of property and equipment: $7,841M (2025), $5,058M (2024), $3,448M (2023)

97%
Source evidence
“Purchases of property and equipment(7,841)(5,058)(3,448)”

Anti-obesity medicines significant portion of revenues; payer access barriers

Anti-obesity medicines comprise a significant portion of revenues; U.S. self-insured employers must opt in for coverage and many international payers do not cover anti-obesity medicines for weight loss.

95%
Source evidence
“Our anti-obesity medicines comprise a significant portion of our revenues, and barriers to reimbursable patient access impact our sales volumes, business, and results of operations.”

November 2025 preliminary voluntary agreements with U.S. government

Preliminary voluntary agreements with the U.S. government to lower Medicaid and certain drug prices and launch new medicines with balanced pricing across developed nations, expanding U.S. access to obesity medicines

96%
Source evidence
“In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.”

Risks, financing, and outlook

Debt issuance and balances

Long-term debt proceeds $13,167M (2025); long-term debt $40,868M and short-term borrowings/current maturities $1,635M at year-end 2025

96%
Source evidence
“Proceeds from issuance of long-term debt13,167 11,417 3,959”

FY2025 revenue growth driven by Mounjaro and Zepbound

Revenue $65,179M in 2025 vs $45,043M in 2024 (+45%), driven primarily by increased volume, partially offset by lower realized prices, primarily driven by Mounjaro and Zepbound

99%
Source evidence
“Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound.”

Adoption of ASU 2023-09 income tax disclosures

Adopted ASU 2023-09 effective January 1, 2025, requiring incremental effective tax rate and income taxes paid disaggregation; evaluating ASU 2024-03 expense disaggregation (effective 2027)

93%
Source evidence
“Effective January 1, 2025, we prospectively adopted Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures”

IRA Medicare price-setting: Jardiance, Trulicity, Verzenio selected

IRA government-set prices: Jardiance effective 2026; Trulicity and Verzenio selected January 2026 effective 2028; company expects other significant products to be selected in future years

96%
Source evidence
“In January 2026, HHS selected Trulicity and Verzenio as additional medicines subject to government-set prices to be effective in 2028. Given our product portfolio, we expect other significant products will be selected in future years.”

Intensifying competition including from China

Intensifying global competition, including from China and other markets with significantly expanded and accelerated R&D capabilities; these companies increasingly license products to multinationals and compete directly in major markets.

95%
Source evidence
“We face intensifying competition worldwide, including from China and other markets that have significantly expanded and accelerated research and development capabilities.”

Pharmaceutical R&D cost and failure risk

High R&D failure risk; must replace revenue of products losing IP protection

95%
Source evidence
“There is a high rate of failure inherent in drug discovery and development.”

Counterfeit and compounded incretins

Counterfeit/mass-compounded incretins in U.S. and other markets threaten brand and results

95%
Source evidence
“we continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets that could materially impact us”

Pricing, reimbursement, and access pressure

Government price controls and payer restrictions already negatively affecting results

95%
Source evidence
“These pressures have negatively affected and we expect will continue to negatively affect our consolidated results of operations.”

Manufacturing capacity expansion and demand-forecast risk

Major manufacturing capacity build-out with long lead times; demand miscalculation risk

95%
Source evidence
“We are continuing the significant expansion of our manufacturing capabilities and substantial investment in long-term supply agreements to fortify our supply and support our ability to meet anticipated demand for our products.”

Payer/PBM pricing pressure and litigation exposure

U.S. private payers and PBMs significantly impact pharmaceutical pricing; litigation and investigations ongoing related to 340B program, insulin access, pricing, and product safety

93%
Source evidence
“we are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters”

Tariff and trade protection exposure

Tariffs and trade protection measures could cause supply disruptions or delays and increase costs; pharmaceutical exemptions may be terminated, and the company may not meaningfully share increased costs

93%
Source evidence
“If enacted, additional restrictions could result in supply disruptions or delays, further increase costs, or otherwise have a negative impact on our business.”

Pricing pressures and U.S. drug pricing agreement

Continued pricing pressures and actions of governmental and private actors affecting pricing, reimbursement, and patient access; negotiation and implementation of a voluntary agreement with the U.S. government related to drug pricing and access.

93%
Source evidence
“negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access”

AI and emerging technology risks

Use of AI or other emerging technologies in operations, including partnerships and sharing with third parties, may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks.

92%
Source evidence
“the use of artificial intelligence or other emerging technologies in various facets of our operations... which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks”

Business development execution risk

M&A/business development risk including FTC and European competition authority scrutiny

90%
Source evidence
“Continued regulatory focus on business combinations in our industry, including by the Federal Trade Commission and competition authorities in Europe”

Biosimilar regulation risk

Evolving biosimilar regulation could accelerate competitor entry against biologics

90%
Source evidence
“Given the importance to us of marketed biologic products and those in our clinical-stage pipeline, such regulation could have a material adverse effect on our business.”

Tariff and geopolitical cost exposure on supply chain

Tariff, inflation, and geopolitical exposure across manufacturing supply chain

90%
Source evidence
“Regional or single-source dependencies may in some cases accentuate risks and costs (e.g., tariffs) related to manufacturing and supply.”

Cybersecurity and data privacy risk

Cyber-attack and data privacy exposure (EU/UK/China/US laws); no material impact to date

90%
Source evidence
“To date, system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches... have not had a material impact on our business strategy, results of operations or financial condition.”

R&D failure risk and pipeline replacement risk

High rate of failure in drug discovery; may not succeed in developing or acquiring products sufficient to replace revenues of products losing IP protection or displaced by competitors

90%
Source evidence
“There is a high rate of failure inherent in drug discovery and development. To bring a product from the discovery phase to market takes considerable time and entails significant cost.”

Single-source raw material risk

Single-source raw/intermediate material availability risk

85%
Source evidence
“(iv) inability to obtain single-source or other raw or intermediate materials”

Talent competition risk

Competition for skilled talent increasing labor costs

85%
Source evidence
“which has increased and may continue to increase our labor costs”

Cannibalization and treatment innovation risk

Self-cannibalization and new modality displacement of existing products

85%
Source evidence
“In some cases, the introduction of our own innovative products results in these adverse impacts for our preexisting products.”

Material exposure graph

Mounjaro / Zepbound (tirzepatide)
Revenue Exposure

2025 revenue growth and volume/price dynamics were primarily driven by Mounjaro and Zepbound, indicating heavy dependence on the tirzepatide franchise.

Relevance 98·Dependency 90·Confidence 98
Source evidence
“The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound.”
Anti-obesity medicines
Revenue Exposure

Anti-obesity medicines comprise a significant portion of revenues; payer coverage restrictions (opt-in by U.S. self-insured employers, non-coverage in some international markets) impact sales volumes.

Relevance 92·Dependency 80·Confidence 93
Source evidence
“Barriers to reimbursable patient access in some cases include default payer coverage restrictions for our medicines.”
McKesson, Cencora, Cardinal Health
Customer Exposure

Three U.S. wholesale distributors each account for a significant percentage of consolidated revenue, concentrating distribution risk.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA government-set Medicare prices apply to Jardiance (2026) and Trulicity/Verzenio (2028), with more significant products expected to be selected, meaningfully influencing business strategies.

Relevance 90·Dependency 80·Confidence 96
Source evidence
“The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.”
Government price controls and reimbursement restrictions
Regulatory Exposure

Public and private pricing/reimbursement restrictions have already negatively affected and are expected to continue to negatively affect consolidated results.

Relevance 90·Dependency 70·Confidence 95
Source evidence
“These pressures have negatively affected and we expect will continue to negatively affect our consolidated results of operations.”
November 2025 U.S. government pricing agreements
Competitive Exposure

Voluntary agreements lower Medicaid/certain drug prices and expand U.S. obesity medicine access; revenues may be insufficient to offset pricing concessions, affecting demand and competitive positioning globally.

Relevance 85·Dependency 75·Confidence 94
Source evidence
“we may fail to adequately capitalize on the additional U.S. access to our obesity medicines resulting from these agreements, particularly if the revenues generated from such expanded access are insufficient to offset pricing concessions.”
Cardiometabolic/incretin R&D pipeline (orforglipron, retatrutide, efsitora)
Revenue Exposure

Extensive Phase 3 and submitted pipeline across obesity, T2D, and cardiovascular indications represents the primary future growth driver and replacement source for the company's long-term revenue.

Relevance 85·Dependency 70·Confidence 92
Source evidence
“Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.”
Incretins
Customer Exposure

Counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets could materially impact results, reputation, and compliant market participation.

Relevance 85·Dependency 60·Confidence 90
Source evidence
“we continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins in the U.S. and other markets that could materially impact us”
U.S. private payers and pharmacy benefit managers
Customer Exposure

U.S. private payers and PBMs negotiate access, price/rebate concessions, and pharmacy reimbursement rates, significantly impacting the market for the company's pharmaceuticals.

Relevance 80·Dependency 70·Confidence 93
Source evidence
“Private payers and pharmacy benefit managers in the U.S. continue to significantly impact the market for pharmaceuticals through negotiation of access, manufacturer price or rebate concessions and pharmacy reimbursement rates.”
U.S. government drug pricing and access voluntary agreement
Regulatory Exposure

Negotiation and implementation of the voluntary U.S. government agreement on drug pricing and access is a disclosed uncertainty affecting pricing and reimbursement.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access”
Research and development spending
Cost Driver

Increased R&D expenses partially offset 2025 net income growth, making R&D spend a key cost driver alongside marketing, selling, and administrative expenses.

Relevance 75·Dependency 65·Confidence 90
Source evidence
“Net income and earnings per share increased in 2025, primarily due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.”
Tariffs
Geopolitical Exposure

Regional/single-source supply dependencies accentuate tariff-related costs; tariffs listed first among external environmental factors raising distribution, construction, and procurement costs.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“Regional or single-source dependencies may in some cases accentuate risks and costs (e.g., tariffs) related to manufacturing and supply.”
Biosimilar regulation
Regulatory Exposure

Guidelines and legislative actions easing biosimilar entry could materially affect the business given the importance of marketed and pipeline biologic products.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“Given the importance to us of marketed biologic products and those in our clinical-stage pipeline, such regulation could have a material adverse effect on our business.”
Product sales customers
Customer Exposure

Net product revenue of $60,958M in 2025 is recognized when customers obtain control of goods, generally at shipment, with 30-70 day payment terms.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer.”
340B program, insulin access, and pricing litigation
Legal Exposure

Litigation and investigations related to the 340B program, access to insulin, pricing, and product safety could adversely impact the business if resolved adversely.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“we are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters that, if resolved adversely to us, could negatively impact our business and consolidated results of operations.”
China
Competitive Exposure

China-based and similar markets' expanded R&D capabilities increase competitive pressure, including licensing to multinationals and direct competition in major markets.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“We face intensifying competition worldwide, including from China and other markets that have significantly expanded and accelerated research and development capabilities.”
Tariffs / trade protection measures
Regulatory Exposure

Tariff exemptions for pharmaceuticals may be terminated; additional restrictions could disrupt supply and increase costs, which the company cannot meaningfully pass on.

Relevance 65·Dependency 55·Confidence 92
Source evidence
“Given the nature of pharmaceutical regulation and commercialization, we may not be able to share the burden of increased costs from tariffs and related impacts to any meaningful degree.”
LillyDirect
Revenue Exposure

LillyDirect direct-to-patient platform is a growing revenue channel in 2025, with new initiatives potentially exposing the company to new or exacerbated risks.

Relevance 65·Dependency 35·Confidence 88
Source evidence
“Sales through LillyDirect represented a growing portion of our business in 2025 and we have launched, and continue to explore, new partnerships and tools”
Boehringer Ingelheim
Revenue Exposure

Collaboration and other revenue includes revenue from the collaboration with Boehringer Ingelheim plus sale of product rights.

Relevance 65·Dependency 5·Confidence 90
Source evidence
“Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim”
Artificial intelligence
Technology Dependency

AI use in operations and partnerships may exacerbate competitive, regulatory, litigation, and cybersecurity risks.

Relevance 60·Dependency 45·Confidence 85
Source evidence
“the use of artificial intelligence or other emerging technologies in various facets of our operations, including partnerships related to the use of, or the sharing of, such technologies with third parties”
USD
Currency Exposure

Non-U.S. subsidiary results are translated at weighted-average rates and net assets at period-end rates, with translation effects recorded in other comprehensive income ($1,241M favorable in 2025).

Relevance 60·Dependency 40·Confidence 85
Source evidence
“The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted-average currency rate for the period.”
Skilled talent competition
Cost Driver

Competition for qualified scientific, technical, and management personnel from multinationals, academia, and nearby employers has increased and may continue to increase labor costs.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“which has increased and may continue to increase our labor costs”
United Kingdom
Revenue Exposure

Disclosed forward-looking risk includes fluctuations in foreign currency exchange rates, interest rates, and inflation/deflation affecting global operations across ~90 countries.

Relevance 55·Dependency 40·Confidence 70
Source evidence
“fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation”
Full company information
Latest profile, trading, valuation, and identifier data stored for LLY.
Share price
$1,431.23
Market cap
$1.35T
Exchange
NYSE
Currency
USD
CEO
David A. Ricks
Employees
50,000
IPO date
01/06/1972
Beta
0.453
Last dividend
$0.00
Day range
$1,426.39 – $1,442.45
52-week range
$850.51 – $1,449.68
1-day performance
1.55%
1-year performance
68.28%
Current drawdown (1Y)
-1.27%
CIK
0000059478
CUSIP
532457108
ISIN
US5324571083
Created
07/12/2025, 05:04:56
Last update
04/11/2026, 15:38:38

Track Eli Lilly and Company with an AI analyst

See which prediction-market events move LLY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to LLY from your Railway `news_articles` table.

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

PRNewsWire • STOCK • 14/06/2026, 05:15:00

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

PRNewsWire • STOCK • 13/06/2026, 13:15:00

Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care

Zacks Investment Research • STOCK • 10/06/2026, 14:01:24

Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Reuters • STOCK • 10/06/2026, 08:02:24

Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 20:52:09

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

PRNewsWire • STOCK • 09/06/2026, 20:18:00

Eli Lilly and Company (NYSE:LLY) Soars on Strong Clinical Trials and Analyst Confidence in Diabetes and Obesity Market

Market Data • Market Data • 09/06/2026, 19:11:23

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Forbes • STOCK • 09/06/2026, 16:03:15

Prediction: Eli Lilly Will Trade at This Price in a Year

24/7 Wall Street • STOCK • 09/06/2026, 15:33:58

Why Eli Lilly Stock Climbed to a New All-Time High Today

The Motley Fool • STOCK • 08/06/2026, 23:13:52

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Invezz • STOCK • 08/06/2026, 15:50:27

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Market Watch • STOCK • 08/06/2026, 08:16:00